Checkpoint inhibitors (ICIs) exhibit substantial promise in combating cancer by restoring or activating the immune system. However, multiple mechanisms contribute to immunotherapy resistance of malignant cells, with the hard-to-penetrate tumor microenvironment (TME) being a major factor that limits the efficacy of ICIs and other immune-modulating therapeutics. Preclinical and clinical data suggests that angiotensin receptor blockers (ARBs), commonly used to treat hypertension, can potentially augment the beneficial effects of ICIs by modifying the TME. However, the systemic administration of ARBs is complicated by their blood pressure-lowering effect.

Revium Rx develops nanoparticle-encapsulated candesartan (approved ARB) as a tumor-targeted and safe adjuvant to ICIs treatment. The novel adjuvant developed by Revium aims to overcome the limitation of systemic ARB administration and significantly improve treatment success rates by enabling enhanced permeability and retention (EPR effect) without affecting systemic blood pressure. Preclinical studies carried out at the Hebrew University of Jerusalem have shown that ARB targeting can effectively modulate the immune response within tumors, increasing the effectiveness of current therapies.

Checkpoint inhibitors (ICIs) exhibit substantial promise in combating cancer by restoring or activating the immune system. However, multiple mechanisms contribute to immunotherapy resistance of malignant cells, with the hard-to-penetrate tumor microenvironment (TME) being a major factor that limits the efficacy of ICIs and other immune-modulating therapeutics. Preclinical and clinical data suggests that angiotensin receptor blockers (ARBs), commonly used to treat hypertension, can potentially augment the beneficial effects of ICIs by modifying the TME. However, the systemic administration of ARBs is complicated by their blood pressure-lowering effect.

Revium Rx develops nanoparticle-encapsulated candesartan (approved ARB) as a tumor-targeted and safe adjuvant to ICIs treatment. The novel adjuvant developed by Revium aims to overcome the limitation of systemic ARB administration and significantly improve treatment success rates by enabling enhanced permeability and retention (EPR effect) without affecting systemic blood pressure. Preclinical studies carried out at the Hebrew University of Jerusalem have shown that ARB targeting can effectively modulate the immune response within tumors, increasing the effectiveness of current therapies.

Solid Tumors